NEW YORK, NY—March 20, 2014 - LifeSci Advisors, LLC and Oramed Pharmaceuticals (NASDAQ: ORMP)
Oramed's Oral Insulin Development Program is in Phase II for the Treatment of Diabetes
Report Available for Download at http://www.lifesciadvisors.com/clients/oramed/
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Oramed Pharmaceuticals (NASDAQ: ORMP), a pharmaceutical company developing a platform technology for the oral delivery of proteins and peptides. The Company's proprietary protein oral delivery (POD™) technology protects proteins during gastrointestinal transport and facilitates absorption into the bloodstream. The Company's lead candidate is ORMD-0801, an oral insulin product that is being tested in different populations of diabetes patients. Oramed is also developing ORMD-0901, an oral version of the GLP-1 agonist exenatide. Oral insulin delivery is similar to pancreatic insulin secretion because after absorption in the intestine it goes directly to the liver, more closely mimicking the natural process than insulin injections. Two Phase II trials with ORMD-0801 are expected to launch in 2014.
"Oramed is leveraging its technology platform to develop an oral insulin product for diabetes," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "If the protein oral delivery technology platform is shown to be a safe and effective way to deliver insulin, it has the potential to improve compliance and quality of life by reducing injections for diabetes patients."
In January 2014, Oramed announced positive topline results from a randomized, placebo-controlled Phase IIa trial of ORMD-0801 in type 2 diabetics. The results indicated that ORMD-0801 was safe and well tolerated with no serious adverse events (AEs) in the study. Oramed is scheduled to present more detailed data from the trial at the 2014 Diabetes Summit on April 24th in Cambridge, MA. Oramed is also expanding the application of their POD™ technology for oral delivery of the GLP-1 receptor agonist exenatide. The Company is planning to launch an ex-US Phase Ib trial in the second quarter of 2014, while concurrently completing 90-day preclinical toxicology studies intended to pave the way to commencement of a US-based Phase IIb trial that is expected to start in the first half 2015.
In a 41 page Initiation Report by LifeSci Advisors, we explain the development path plus detailed clinical and preclinical data for Oramed's oral insulin and oral exenatide programs. The report details Oramed's clinical development strategy for type 1 and type 2 diabetes mellitus. We examine the treatment landscape and competition for insulin, and critically examine competing products and development programs.
Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.
Phone: (646) 597-6979
SOURCE: LifeSci Advisors